News
FDA approves buprenorphine injection for opioid use disorder
Brixadi is approved in both weekly and monthly subcutaneous injectable formulations at varying doses.
News
FDA clears diagnostic test for early Alzheimer’s
“There is a new option that can typically be completed the same day and can give doctors the same information regarding brain amyloid status,...
News
FDA okays new drug option for schizophrenia, bipolar I disorder
The FDA approved Lybalvi under the 505(b)(2) regulatory pathway based on data from 27 clinical studies.
News
FDA approves first IV migraine prevention drug
“The PROMISE-2 data showed that many patients can achieve reduction in migraine days of at least 75% and experience a sustained migraine...